Integrating AI Agents with Veradigm

Three that matter, and Veradigm is unusually honest about what each one costs.

Almost no other EHR vendor publishes this. It is genuinely useful, and it lets you do something you cannot do on Epic or Oracle Health: work out roughly what an agent vendor is paying to reach you, and therefore what part of your subscription is covering it. We ask the same question on every platform, which is why the EHR integration pages share a shape.

It is, and pretending otherwise would not help you. Of the major ambient documentation vendors, most publish integrations with Epic, Oracle Health, athenahealth or MEDITECH and do not name Veradigm. Suki, Nabla, Ambience, Abridge and DeepScribe all fall into that group on the public record as of mid 2026.

The exceptions are instructive rather than reassuring. Waystar documents a Veradigm partner integration on the revenue cycle side. Heidi Health, a smaller ambient vendor, publishes a Veradigm integration describing schedule sync and note push. Microsoft's ambient product reaches Allscripts environments largely through implementation partners using a generic text input approach rather than a named API integration.

Three plausible reasons, and you should assume all three are operating. The published API economics above create a real per client cost that scales badly for a vendor selling into many small practices. Veradigm sells its own ambient scribe into the same workflow. And the corporate situation covered below makes some vendors cautious about committing engineering to the platform.

What this means for you is narrower choice, not impossibility. It also means you should be sceptical of any vendor asserting Veradigm support without a named production reference, because the base rate of genuine integrations here is low. The scribe comparison sets out which vendors document which platforms.

It makes the first party option the default rather than one of several, which is a stronger position than the same product would have on a platform with a crowded ecosystem.

Veradigm Ambient Scribe launched in 2024, and Veradigm announced a significant enhancement in November 2025 covering structured ICD-10 diagnosis code recommendations, multi language capture including Spanish, Mandarin and Arabic with English structured note output, and symptom and care plan suggestions. Those are substantive capabilities, not a checkbox product.

Be careful with one of them. Diagnosis code recommendation is a materially different risk profile from note drafting, because it touches billing and therefore compliance. Anything suggesting codes belongs in the same governance conversation as medical coding automation, with documented human review, rather than being adopted as a documentation convenience.

The honest summary: on Veradigm the first party scribe is a reasonable place to start, because the alternatives are few and the integration friction for outsiders is real. Test it against your own encounters rather than adopting it because it is there.

Yes, as a diligence item rather than an alarm, and it should be handled by whoever signs your contracts rather than by your clinicians.

The public record is that Veradigm's board determined in 2023 that certain prior financial statements could no longer be relied upon, that Nasdaq suspended trading in February 2024 and filed to delist that April, leaving the shares trading over the counter, and that the company filed its restated 2022 annual report in March 2025. In January 2025 Veradigm concluded a strategic alternatives review and announced it would remain an independent standalone public company. As of a filing in May 2026 it remained delinquent on multiple quarterly and annual reports.

What follows practically is not that you should avoid the platform. Thousands of practices run on it and it remains certified. What follows is that the usual reassurance of reading a recent annual report before a multi year commitment is not available to you, so you compensate elsewhere: shorter initial terms, clearer data export and termination assistance clauses, and a written answer on what happens to your data and your integrations if ownership changes. That is contract work, and it is the kind of thing our vendor selection engagement exists to surface before signature.

The usual list, with two additions specific to this platform.

• Confirm whether you are a Veradigm or an Altera customer, in writing, before any evaluation starts.
• Name one integration owner with authority across all your sites.
• Ask each vendor which access path they use, Unity or certified FHIR, and what tier they hold. The answer predicts what they can build and what they will charge.
• Ask for a named production reference on Veradigm specifically, not on Allscripts generally.
• Run the business associate agreement in parallel with the technical work.
• Agree what gets written back, into which fields, and who validates it against real encounters.

Turning that into a dated sequence with owners is what a deployment roadmap produces, and on a platform with a thin ecosystem the sequencing matters more, because there is less room to switch vendors mid project.

Real leverage, and this is a platform where you may need it.

Certified health IT has to publish its API documentation and its terms, which is part of why the free open account tier and the published price list exist at all. The information blocking provisions constrain what a developer may do to obstruct access to electronic health information, and a fee structure is not automatically obstruction, but an unexplained refusal to connect a vendor you have chosen is a conversation worth having with the rules to hand.

The HTI-1 rule also brought transparency requirements for predictive decision support shipped inside certified software. Given that Veradigm's own scribe now suggests diagnosis codes, those disclosures are something your compliance function should hold on file rather than request after an audit question.

Separately, integration approval and privacy approval run on different clocks. Ask where audio and transcripts live, how long they are kept, whether your data trains shared models and what happens at termination. The HIPAA and AI page covers what to insist on.

Revenue cycle work is the unusual answer here, and it is the right one more often than on other platforms. Waystar documents a Veradigm integration, Payerpath already sits in that workflow, and the business case at an independent ambulatory practice is easier to defend than a documentation case. Revenue cycle automation and prior authorization are the usual entry points.

Ambient documentation is second, and on this platform that realistically means evaluating the first party scribe first and a small number of outside options second. That is a narrower field than a practice on athenahealth would face, and it is better to know that going in.

Patient access and phone agents are third and currently the hardest to source with verified integrations. If that is your priority, weigh it in any platform decision you are already considering. Anything that orders, prescribes or codes without human review belongs behind a governance process rather than in a pilot.

If you want the money framing before the technical one, the ROI calculator shows its assumptions on the page so you can substitute your own.

Establish the two platform facts first: Veradigm or Altera, and which access path your candidate vendors hold. Those answers remove more options than any feature comparison will, and they take a week rather than a quarter.

Then start where the integration exists rather than where the marketing is loudest. On a platform with a thin ecosystem, a working revenue cycle agent delivered this year beats a documentation project waiting on an integration that no vendor has committed to build.

If you are weighing a platform move as part of this, read athenahealth, NextGen and eClinicalWorks alongside this page, because the ecosystem question is the one that differs most between them. Turning that into a decision your partners will sign off is what our deployment roadmap work produces.